Agonistic immune checkpoint regulator may harm the heart

Abstract

The use of cancer immunotherapies is expanding to patients resistant to current therapies, and emerging regulators of immune checkpoints such as agonist antibodies that directly activate immune responses are being studied. Although these therapeutics are promising, this study highlights the potential for cardiac immune-related adverse events.